Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026
Key Highlights
- ➤ALARIC phase 1: all four D8 CAR-T patients achieved rapid complete hematological responses
- ➤ALARIC patients showed good tolerability and encouraging organ-function improvements at five months
- ➤Delayed MRD negativity after obe-cel produced outcomes comparable to early responders
- ➤ddPCR and qPCR results sufficiently concordant to support commercial qPCR monitoring in practice
Expert Statements
Elias Jabbour, D.B. Lane Cancer Research Fund Distinguished Professor in Leukemia Research; Section Chief, Acute Lymphoblastic Leukemia, MD Anderson Cancer Center
“MRD responses continued to deepen beyond month one, with patients who achieved delayed MRD negativity experiencing outcomes comparable to early responders.”
Aaron Logan, Professor of Medicine; Director, Cellular Therapy Program, Division of Hematology, Blood and Marrow Transplant, and Cellular Therapy, University of California, San Francisco
“Concordance between the ddPCR and qPCR assay results within this subset of patients from FELIX is sufficient and acceptable to support the use of the commercially available qPCR assay for patients in clinical practice.”
LONDON and GAITHERSBURG, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced the online publication of abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held December 12-15, 2026, in New Orleans, Louisiana.
Abstract 4498 – Oral Presentation Title: What to expect during the first 3 months post obecabtagene autoleucel (obe-cel) infusion in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): A deepening of measurable residual disease (MRD) response and recovery from cytopenias Session name: Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Relapsed/Refractory Acute Lymphoblastic Leukemia: From Novel CAR T-cell Constructs to Real-World Experience in B-ALL, and an Investigational Agent in T-cell ALL Presentation date and time: December 12, 2026; 5:00 - 5:15 PM ET Presentation room: MCCNO - 265-268 Publication number: 377 Presenting author: Elias Jabbour, MD; D.B. Lane Cancer Research Fund Distinguished Professor in Leukemia Research; Section Chief Acute Lymphoblastic Leukemia; MD Anderson Cancer Center, Houston, Texas
Get started
Create a free account to read the full story.